



Phyllis Arthur is the Executive Vice President & Head of Healthcare Policy and Programs at the Biotechnology Innovation Organization (BIO). In this role Ms. Arthur is responsible for leading on a robust portfolio of healthcare policy issues with member companies, including on pricing, reimbursement, and access, infectious disease, national security, and capital formation. Previously she served as the SVP for Infectious Disease and Emerging Science Policy, working with member companies in vaccines, antimicrobial resistance and biodefense on policy, legislative and regulatory issues. Ms. Arthur joined BIO in July 2009 as the Director of Healthcare Regulatory Affairs.

Prior to joining BIO, she worked in numerous marketing and sales positions for Merck & Co Inc in their Vaccine Division. Over her 16-year career at Merck, Ms. Arthur launched several exciting new vaccines in the United States and internationally, including the first HPV vaccine, GARDASIL. During her years in Marketing, she worked closely with clinical and academic thought leaders in infectious diseases, oncology and public health. In addition, Ms. Arthur also led a large vaccine sales organization of over 75 representatives and managers covering 14 states.

Before graduate school, Ms. Arthur worked as a research assistant for two economists at the Brookings Institution in Washington, DC. There she conducted economic analyses related to savings and investment policies for the OECD countries.

Ms. Arthur received her B.A. in 1987 in Economics and International Politics from Goucher College and her M.B.A. in 1991 from the Wharton School of Business at the University of Pennsylvania.